| Factor Information | |
|---|---|
| Data ID | 2316 |
| Factor | 6-MWD, m |
| Description | Mean 6MWD for patients on bosentan monotherapy (n=8) was 440.1 ± 103.8 m, whereas for patients on bosentan-sildenafil combination therapy (n=4) it was 428.8 ± 96.9 m, after four years of therapy. |
| Biomarker | NA |
| Classification | C3 (lifestycle factor - exercise habit) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | We examined the short- and long-term effects and safety profile of bosentan in patients with PAH and complex CHD. |
| p Value | 0.005 |
| Conclusion | Mean 6MWD for patients on bosentan monotherapy (n=8) was 440.1 ± 103.8 m, whereas for patients on bosentan-sildenafil combination therapy (n=4) it was 428.8 ± 96.9 m, after four years of therapy. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 596 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD/TA/PDA/TGA |
| Reference | |
|---|---|
| PMID | 23351920 |
| Year | 2013 |
| Title | Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | Database | |
| Region | Coimbra, Portugal | |
| Method | We followed 14 patients with PAH and complex CHD for a mean of four years. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | Right heart catheterization | |
| Group | Four years after bosentan therapy(Treatment) | Baseline(Control) |
| Number | 8 | 14 |
| Age | 37.1±11.7 years | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 440.1±103.8 m | 371.9±90.3 m |
